Cancer of the prostate. Mechanisms of action of antiandrogens.
Habenicht
U F
UF
N.V. Schering S.A., Diegem.
Neumann
F
F
el Etreby
M F
MF
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000818:Animals; D003534:Cyproterone / Q000031:analogs & derivatives / Q000494:pharmacology; D017373:Cyproterone Acetate; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D013739:Testosterone / Q000378:metabolism
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017373:Cyproterone Acetate; D005485:Flutamide; D007986:Luteinizing Hormone; D003534:Cyproterone